Exploring the Inflammatory Signature of the anti-cancer Smac-mimetic, Birinapant, and the contribution of this signature to Birinapant anti-Tumour activity

程序性细胞死亡(PCD)是去除癌细胞的重要过程。PCD的缺陷现在被认为是癌症发生和化疗耐药的一个原因。被称为IAPs的蛋白质保护癌细胞免受PCD的影响，然而，IAPs的抑制剂已经开发出来在这方面杀死癌细胞。事实上，IAP抑制剂还可以促进炎症，这可能会改善或阻碍它们杀死癌细胞的效果，这是我们现在希望探索和利用的问题。

Programmed cell death (PCD) is an essential process for the removal of cancer cells. Defects in PCD are now known to be a causal factor in cancer initiation and chemotherapeutic resistance. Proteins called IAPs protect cancer cells from PCD, however, inhibitors of IAPs have been developed to kill cancer cells in this respect. Indeed, IAP inhibitors can also promote inflammation, which may improve or hamper their efficacy in killing cancer cells, an issue we now wish to explore and exploit.